Topic: translational medicine
News of the hires comes weeks after Schrödinger pulled in more cash to fund its evolution into a biotech with an internal pipeline.
Thomas Hultsch will build LEO Pharma’s translational medicine presence in the U.S. and Europe.
The move sees Saha end his near-10-year spell away from Big Pharma for the chance to run Bristol-Myers’ translational medicine operation.
Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical trials of new cancer medicines.